 Positive results from Mesoblast Limiteds NASDAQ: MESO chronic back pain treatment trial have boosted investor confidence sending the companys shares higher in the premarket after an announcement showing its stem cell treatment for chronic lower back pain is safe, durable, and effective. Phase 3 trial results have shown that a single injection of rexlemestrocel-L in 404 enrolled patients suffering from lower back pain due to degenerative disc disease results in at least two years of pain reduction. 